{
    "nct_id": "NCT03535194",
    "official_title": "A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Efficacy and Safety of Mirikizumab to Secukinumab and Placebo in Patients With Moderate-to-Severe Plaque Psoriasis OASIS-2",
    "inclusion_criteria": "* Participant must have chronic plaque psoriasis for at least 6 months.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Participant must not be breastfeeding or nursing woman.\n* Participant must not have had serious, opportunistic, or chronic/recurring infection within 3 months.\n* Participant must not have received a Bacillus Calmette-Guerin (BCG) vaccination within 12 months or received live vaccine(s) (including attenuated live vaccines) within 12 weeks of baseline or intend to receive either during the study.\n* Participant must not have any other skin conditions (excluding psoriasis).\n* Participant must not have previous exposure to Cosentyx and any other biologic therapy targeting IL-17 (including Taltz).\n* Participant must not have received anti-tumor necrosis factor (TNF) biologics within 8 weeks.\n* Participant must not have previous exposure to any biologic therapy targeting IL-23 (including Stelara).",
    "miscellaneous_criteria": ""
}